CSIMarket Company Name, Ticker, Suppliers, else..


Reshape Lifesciences Inc   (NASDAQ: RSLS)
Other Ticker:  
 

Reshape Lifesciences Inc

RSLS's Fundamental analysis



Reshape Lifesciences Inc 's sales fell by -42.75 % in the first quarter of 2025 from the same quarter a year ago. Ranking at No. 2091

Major Pharmaceutical Preparations industry recorded growth of revenues by 4.44 %

Reshape Lifesciences Inc realized net income compared to net loss a year ago in first quarter of 2025

• More on RSLS's Growth


Reshape Lifesciences Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Reshape Lifesciences Inc PEG ratio is at -0 Company is currently trading with Price to Cash flow multiple of 0.05 in trailing twelve-month period.
Company
0.01
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 0.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.39.


• More on RSLS's Valuation
 
 Total Debt (Millions $) -
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 95,785
 Net Income/Employee (TTM) $ -53,277
 Receivable Turnover (TTM) 5.6
 Tangible Book Value (Per Share $) 395.92

Reshape Lifesciences Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Reshape Lifesciences Inc PEG ratio is at -0 Company is currently trading with Price to Cash flow multiple of 0.05 in trailing twelve-month period.
Company
0.01
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 0.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.39.

Reshape Lifesciences Inc Price to Book Ratio is at 0.01 lower than Industry Avg. of 34.45. and equal to S&P 500 Avg. of 0.01

• More on RSLS's Valuation

•  Market Capitalization (Millions $) 0
•  Shares Outstanding (Millions) 0
•  Employees 65
•  Revenues (TTM) (Millions $) 6
•  Net Income (TTM) (Millions $) -3
•  Cash Flow (TTM) (Millions $) 0
•  Capital Exp. (TTM) (Millions $) -
•  Total Debt (Millions $) -
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 95,785
•  Net Income/Employee(TTM) $ -53,277
•  Receivable Turnover Ratio (TTM) 5.6
•  Tangible Book Value (Per Share $) 395.92

•  Market Capitalization (Millions $) 0
•  Shares Outstanding (Millions) 0
•  Employees 65
•  Revenues (TTM) (Millions $) 6
•  Net Income (TTM) (Millions $) -3
•  Cash Flow (TTM) (Millions $) 0
•  Capital Exp. (TTM) (Millions $) -





  Ratio
•   Capital Ratio (MRQ) 1.53
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) 4.27
•  Asset Turnover Ratio (TTM) 1.07
•  Inventory Turnover Ratio (TTM) 0.92





Reshape Lifesciences Inc net profit margin of 132.43 % is currently ranking no. 4 in Major Pharmaceutical Preparations industry, ranking no. 10 in Healthcare sector and number 55 in S&P 500.

• More on RSLS's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com